KIM-1 May Predict Higher-Risk Disease in Kidney Cancer

News
Video

KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.

Higher levels of kidney injury molecule 1 (KIM-1) expression may predict more aggressive disease in patients with early-stage kidney cancer or a higher likelihood of recurrence among patients with resected renal tumors, according to Wenxin (Vincent) Xu, MD.

Xu, a medical oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School, gave CancerNetwork® an overview of a presentation he gave on KIM-1 as a prognostic tool for kidney cancers at the 2025 Kidney Cancer Research Summit.

He began by describing KIM-1 as a protein typically overexpressed in kidney cancer cells that can be detected in the bloodstream. Xu suggested that the biomarker could be used as a noninvasive means of detecting kidney cancer and that its utility could be applied to diagnosis, risk stratification, and monitoring disease treatment.

He further expressed that it could be used as a predictive measure in a variety of settings, such as higher levels of KIM-1 predicting higher-risk tumors in early-stage disease or a higher likelihood of recurrence in patients with resected renal tumors. Xu concluded by stating that patients who experience diminished KIM-1 levels within the first 3 weeks of immunotherapy exhibit better long-term outcomes.

Transcript:

KIM-1, which is also called kidney injury molecule 1, also called TIM-1, is a protein that’s overexpressed in kidney cancer cells. The protein is at high levels on the surface of kidney cancer. There’s a section of the protein, the extracellular domain, which is cleaved off into the blood and is detectable. It’s a blood biomarker that you can detect in the blood. The benefit of KIM-1 [is] it’s a noninvasive way to detect kidney cancer. What we found through several studies across disease stages in kidney cancer is that you can use KIM-1 to diagnose, risk-stratify, detect, and monitor disease treatment.

Specifically, in patients who [have] early-stage [disease] with a renal mass, [high levels of] KIM-1 in the blood can predict a more aggressive [and higher-risk] tumor. In patients who have undergone surgery and have their tumors removed, if the KIM-1 levels remain high, those patients are more likely to recur and benefit more from adjuvant immunotherapy. In [patients in the] metastatic [setting], higher levels of KIM-1 predict more aggressive disease and worse overall prognosis. Patients who have an improvement in KIM-1 after 3 weeks of immunotherapy, so 1 dose of treatment…do well long term.

Reference

Xu W. From bench to bedside: advancing KIM-1 as a tool for clinical decision-making. Presented at: 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Related Content